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ABSTRACT
Introduction: Insulin degludec (degludec) is a
basal insulin with an ultra-long, stable action
profile and reduced pharmacodynamic
variability. Seven phase 3a trials compared
degludec with insulin glargine (glargine).
Patient-level meta-analyses were performed to
obtain a comprehensive overview of differences
between the insulin preparations, possible
because consistent outcome definitions were
utilized.
Methods: Three categories of trials were
analyzed: basal–bolus-treated type 1 diabetes
mellitus (T1DMB/B), insulin-naı¨ve type 2
diabetes mellitus (T2DMinsulin-naı¨ve), and basal–
bolus-treated T2DM (T2DMB/B). Regression
models were adjusted for baseline
characteristics. Endpoints analyzed were
glycosylated hemoglobin (HbA1c), fasting
plasma glucose (FPG), insulin dose and
hypoglycemic rates analyzed in mutually
exclusive groups: non-severe nocturnal, non-
severe daytime, and severe.
Results: As with previous treat-to-target trials,
reductions in HbA1c were similar between
degludec and glargine. Reductions in FPG were
significantly greater with degludec in T1DMB/B
and T2DMinsulin-naı¨ve. Total daily insulin dose
was significantly lower with degludec in
T1DMB/B and T2DMinsulin-naı¨ve. Estimated
hypoglycemia rate ratios for degludec/glargine
were as follows for T1DMB/B, T2DMinsulin-naı¨ve
and T2DMB/B, respectively: non-severe
nocturnal 0.83, 0.64, 0.75 (all P\0.05); non-
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severe daytime 1.14 [not significant (ns)], 0.89
(ns), and 0.83 (P\0.05). Rate ratios for severe
events were 1.12 (ns) (T1DMB/B); 0.14 (P\0.05)
(T2DMinsulin-naı¨ve); and not analyzed (T2DMB/B)
due to too few events.
Conclusions: Compared with glargine,
degludec is associated with equivalent HbA1c
control and significantly lower nocturnal
hypoglycemia rates. In T1DMB/B and
T2DMinsulin-naı¨ve, degludec is also associated
with significantly greater reductions in FPG
and lower total doses of insulin versus glargine.
Keywords: Fasting plasma glucose;
Glycosylated hemoglobin (HbA1c);
Hypoglycemia; Insulin degludec; Insulin dose;
Insulin glargine; Type 1 diabetes mellitus; Type
2 diabetes mellitus
INTRODUCTION
The need for effective glycemic control in type 1
(T1DM) and type 2 diabetes mellitus (T2DM) to
prevent the development of complications is
well understood. However, hypoglycemia and
the fear of hypoglycemia, as well as weight gain,
impair both patients’ and physicians’
willingness to titrate insulin to the doses
required to achieve guideline-recommended
target levels of glycemia [1–3]. With the two
basal insulin analogs, insulin glargine (glargine)
and insulin detemir (detemir), the risk of
hypoglycemia is lower than with older human
insulin formulations [4]. Nevertheless, there is
still room for improvement in the
pharmacokinetics and pharmacodynamics of
basal insulin preparations, and consequently
the search has continued for a basal analog with
less variability in pharmacodynamic effect and
a longer duration of action than those currently
available to fulfil requirements in all patients
with once-daily administration.
Insulin degludec (degludec) is a next-
generation basal insulin with an ultra-long
and stable action profile and lower
pharmacodynamic variability than glargine [5,
6]. Degludec has been designed to form long,
soluble multi-hexamer chains upon injection
into the subcutaneous tissue; insulin monomers
gradually dissociate from these [7]. This
mechanism of protraction results in a flat and
stable pharmacokinetic and pharmacodynamic
profile [6]. Degludec has a half-life of
approximately 25 h in patients with T2DM [6]
and a glucose-lowering effect at steady state in
patients with T1DM beyond 42 h [8].
The efficacy of degludec once daily was
examined in a large clinical development
program, BEGIN, which included nine 26- or
52-week trials. Three trials were versus glargine
in basal–bolus therapy in T1DM [9, 10] and
T2DM [11], and four trials were versus glargine
in basal–oral therapy in T2DM [12–15]. In
addition, degludec was compared with
sitagliptin in a basal–oral trial in T2DM [16],
and with detemir in a basal–bolus trial in T1DM.
In all seven trials in which it was compared with
glargine, degludec showed non-inferiority with
respect to mean decrease in glycosylated
hemoglobin (HbA1c). Rates of confirmed
hypoglycemia and, in particular, nocturnal
confirmed hypoglycemia, were either similar
with the two insulins or significantly lower with
degludec. A pre-planned meta-analysis of
hypoglycemia associated with the two
treatments has already been published [17].
This meta-analysis confirmed that degludec is
associated with a lower risk of hypoglycemia, in
particular nocturnal confirmed hypoglycemia,
compared with glargine. The reductions in
hypoglycemia were even more marked in the
maintenance period (i.e., after 16 weeks, when
the initial up-titration was completed).
Nocturnal hypoglycemia is a particularly
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useful outcome for reflecting differences
between basal insulins, as it is less likely than
daytime hypoglycemia to be confounded by the
effect of bolus insulin, meals, and activity.
Previously, confirmed hypoglycemia included
both severe and non-severe events. To avoid
double counting of events in health economic
models, the new meta-analyses reported here
regrouped the confirmed events into three
mutually exclusive groups: non-severe
nocturnal, non-severe daytime, and severe
hypoglycemia. The division of non-severe events
into daytime and nocturnal was included to
provide evidence on whether the documented
reduction in nocturnal events with degludec was
offset by a change in daytime events.
Individual studies also demonstrate a
significantly or numerically lower insulin dose
with degludec compared with glargine in T1DM
[9, 10] and in T2DM [12–15]. In the new meta-
analyses reported here, we investigated whether
these findings could be confirmed.
Hypoglycemia and HbA1c are the two
endpoints generally considered of most interest
when evaluating diabetes therapy. However,
other endpoints such as fasting plasma glucose
(FPG), insulin dose, and health-related quality of
life (HRQoL) should also be considered to obtain
a global view of the effectiveness of one therapy
compared with another. Individual trials (in any
field of medicine) are frequently under-powered
to show significant differences in secondary
endpoints, and meta-analysis is often required
to reveal whether such differences exist. The
BEGIN program was carefully designed with
consistent definitions of outcomes across all
trials, thus facilitating subsequent meta-analysis
of the data.
This paper reports the results of a
comprehensive set of patient-level meta-analyses
that were performed to compare degludec and
glargine with regard to HbA1c (the primary
endpoint in the trials), and hypoglycemia, FPG,
and dose (secondary endpoints). The objective
was to obtain a comprehensive overview of all
relevant differences between degludec and
glargine, adding to evidence on hypoglycemia
[17] and HRQoL [18, 19].
METHODS
Trials Included in the Meta-Analysis
Table 1 lists all the trials in the BEGIN program
that compared degludec once daily with
glargine once daily and explains how they
were categorized for the current meta-analysis.
Some of the trials included in this analysis were
randomized in a 2:1 or 3:1 manner. This
unequal randomization is consequently
reflected in the meta-analysis with more
patients allocated to degludec than to
glargine. Trials of degludec against insulin
detemir and sitagliptin were not included in
the meta-analysis as the purpose was to
compare degludec against glargine.
The category T1DMB/B (T1DM treated with
basal–bolus therapy) included all patients from
the BEGIN BB T1 Long (NCT00982228) and
BEGIN Flex T1 (NCT01079234) trials [9, 10],
except for patients in one degludec dosing arm
in the BEGIN Flex T1 trial. Patients in the
excluded arm received degludec at extreme
ranges of daily dosing intervals, alternating
dose time in the morning and evening; hence,
inclusion of these data in the meta-analyses
would be potentially confounding. The
category T2DMinsulin-naı¨ve included patients, all
of whom were insulin-naı¨ve, starting on basal–
oral therapy in the BEGIN Once Long
(NCT00982644), BEGIN Once Asia
(NCT01059799) and BEGIN Low Volume
(NCT01068665) trials (U200) [12, 14, 15]. The
BEGIN Flex trial (NCT01006291) in type 2
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diabetes [13] was excluded from the meta-
analysis as it included degludec used at
extreme daily dosing intervals and also
included patients already on insulin. One trial,
BEGIN BB (NCT00972283) [11], compared
degludec with glargine in basal–bolus therapy
in T2DM (T2DMB/B).
Methodology of the Individual Phase 3a
Trials
All of the trials included in the current meta-
analyses were randomized, treat-to-target,
parallel-group, open-label, non-inferiority trials
comparing degludec once daily with glargine
once daily. All procedures followed in the trials
were in accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008. Informed consent was
obtained from all patients for being included in
the studies. The analyses in this article do not
involve any new studies of human or animal
subjects performed by any of the authors.
The treat-to-target design was used, targeted
at self-measured blood glucose \5 mmol/L,
based on a mean of three consecutive days’
measurements. Treating to a common target,
recommended by the FDA [20], allows for
interpretation of any between-treatment
differences in the frequency and severity of
hypoglycemia without being confounded by
differences in glycemic control. The primary
Table 1 Phase 3a trials comparing insulin degludec once daily with insulin glargine once daily in the BEGIN program:
categorization for the meta-analysis [9–15]
Trial
number










[9] T1DMB/B 52 629 IDeg 472, IGlar 157
3770 BEGIN Flex
T1a




[15] T2DMinsulin-naı¨ve 52 1,030 IDeg 773, IGlar 257
3586 BEGIN Once
Asia
[14] T2DMinsulin-naı¨ve 26 435 IDeg 289, IGlar 146
3672 BEGIN Low
Volume
[12] T2DMinsulin-naı¨ve 26 460 IDeg 230, IGlar 230
3668 BEGIN Flexb [13] Not included 26 687 IDeg FF 229, IDeg 228,
IGlar 230
3582 BEGIN BB [11] T2DMB/B 52 1,006 IDeg 755, IGlar 251
BB basal–bolus, FF forced ﬂexible, T1DMB/B basal–bolus-treated type 1 diabetes mellitus, T2DMB/B basal–bolus-treated
type 2 diabetes mellitus, T2DMinsulin-naı¨ve insulin-naı¨ve type 2 diabetes mellitus
a Trial 3770 included a forced ﬂexible-dosing arm with dosing intervals of 8 and 40 h. This arm was excluded from the
meta-analysis as the extreme ﬁxed ﬂexible-dosing intervals do not reﬂect the recommended use of insulin degludec in clinical
practice
b Trial 3668 was excluded from the meta-analysis of T2DMinsulin-naı¨ve as it included degludec used at extreme daily-dosing
intervals and also patients treated with basal insulin at baseline
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endpoint was the difference between treatment
groups in the change in HbA1c from baseline to
study end. Non-inferiority was defined as an
upper limit of B0.4% points for the 95%
confidence interval for the treatment difference.
In all the trials (and for the purposes of meta-
analysis), FPG measurements were performed in
a central laboratory; hypoglycemia was self-
reported; only confirmed hypoglycemic events
(plasma glucose\3.1 mmol/L or severe episodes
requiring assistance) were included in the
analyses; and nocturnal hypoglycemia was
defined as episodes with onset from 00:01 to
05:59 am, inclusive.
Statistical Analysis
Meta-analyses were performed on patient-level
data. The analyses examined the following
endpoints: HbA1c, FPG, insulin dose, and
hypoglycemia. A linear model was used to
analyze HbA1c and FPG. For insulin dose, the
endpoint was log-transformed and analysis of
variance (ANOVA) was used. Hypoglycemia was
analyzed using a negative binomial regression
model. Due to the low number of severe
hypoglycemic episodes in T2DMinsulin-naı¨ve,
this analysis was performed with a Poisson
regression model using a log-link. The a priori
level of significance was set as 0.05 and the
statistical package used was SAS software
version 9.4 (SAS Institute Inc., Cary, NC, USA).
All the meta-analysis regression models were
adjusted for trial, type of diabetes, antidiabetic
therapy at screening, sex, region, and age.
Except for hypoglycemia, all the models
included baseline value as a covariate.
RESULTS
Glycemic Control
As expected in treat-to-target trials, there was
no statistical difference between treatments in
reducing HbA1c: degludec was non-inferior to
glargine in T1DMB/B, T2DMinsulin-naı¨ve, and
Table 2 Meta-analysis comparing insulin degludec once daily with insulin glargine once daily: HbA1c and FPG [9–12, 14,
15]
Category Trials Change in HbA1c (%-points): IDeg–IGlar Change in FPG (mmol/L): IDeg–IGlar













0.08 –0.01; 0.16 IDeg 1,278
IGlar 627
-0.34* -0.54; -0.15
T2DMB/B 3582 IDeg 744
IGlar 248
0.08 –0.05; 0.21 IDeg 740
IGlar 248
-0.29 -0.65; 0.06
CI conﬁdence interval, FPG fasting plasma glucose, HbA1c glycosylated hemoglobin, IDeg insulin degludec, IGlar insulin
glargine, n number of patients, T1DMB/B basal–bolus-treated type 1 diabetes mellitus, T2DMB/B basal–bolus-treated type 2
diabetes mellitus, T2DMinsulin-naı¨ve insulin-naı¨ve type 2 diabetes mellitus
* Signiﬁcant based on 95% CI
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T2DMB/B (Table 2). These results confirmed the
non-inferiority documented in each individual
trial.
End-of-trial reduction in FPG was
significantly greater with degludec than with
glargine in T1DMB/B and T2DMinsulin-naı¨ve
(P\0.05), and numerically (but not
significantly) greater in T2DMB/B (Table 2).
Insulin Dose
In T1DMB/B, the total daily dose of insulin was
significantly lower, by 12%, with degludec
compared with glargine (P\0.0001) (Table 3).
Statistical analyses were performed for both
basal and bolus insulin doses to clarify the
relative contribution of each to the observed
reduction in total dose. These showed that the
daily basal and bolus doses were both lower
with degludec, with relative rates (degludec
versus glargine) as follows: daily basal dose,
0.87; daily bolus dose, 0.88 (both P\0.05).
The total daily insulin dose was also
significantly lower (by 10%, P = 0.0004) with
degludec in T2DMinsulin-naı¨ve. In T2DMB/B, total
daily insulin dose did not differ statistically
between treatments (Table 3).
Hypoglycemia Analyzed in Mutually
Exclusive Groups
The actual event rates for the mutually
exclusive groups used in the current meta-
analysis are shown in Table 4. Event rates for
the individual trials are available in the earlier
papers [11, 17]. The estimated hypoglycemia
rate ratios for the current meta-analysis are
shown in Table 5. These results showed
significantly lower rates of nocturnal non-
severe hypoglycemia with degludec in T1DMB/
B, T2DMinsulin-naı¨ve, and T2DMB/B (by 17, 36, and
25%, respectively; all P\0.05). With degludec,
rates of daytime non-severe hypoglycemia were
significantly lower than with glargine (by 17%;
P\0.05) in T2DMB/B, with no statistical
differences in T1DMB/B and T2DMinsulin-naı¨ve.
Rate ratios for severe events, analyzed in the
previous meta-analysis (and not re-analyzed, as
the definition remained unchanged) [17], were
1.12 [not significant (ns)] (T1DMB/B); 0.14
Table 3 Total daily insulin dose [basal ? bolus (if relevant)] in U/kg (adjusted for covariatesa)
Category IDeg IGlar Estimated treatment
ratio (95% CI)a
T1DMB/B n = 634 n = 314
End of trial 0.68 U/kg 0.77 U/kg 0.88*** (0.85; 0.92)
T2DMinsulin-naı¨ve n = 1,267 n = 625
End of trial 0.39 U/kg 0.43 U/kg 0.90** (0.85; 0.96)
T2DMB/B n = 749 n = 249
End of trial 1.22 U/kg 1.18 U/kg 1.03 (0.97; 1.10)
Data are observed mean and week 52 values are presented with the LOCF approach
ANOVA analysis of variance, CI conﬁdence interval, LOCF last observation carried forward, IDeg insulin degludec, IGlar
insulin glargine, n number of patients, T1DMB/B basal–bolus-treated type 1 diabetes mellitus, T2DMB/B basal–bolus-treated
type 2 diabetes mellitus, T2DMinsulin-naı¨ve insulin-naı¨ve type 2 diabetes mellitus
** P = 0.0004; *** P\0.0001
a Estimated using ANOVA with treatment, sex, antidiabetic therapy at screening, age, and baseline dose as covariates
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Table 5 Hypoglycemia rate ratios in the current meta-analysis during the full trial period, and in the maintenance period
Category Trials Full trial perioda Maintenance periodb
n (total) Estimated rate ratio IDeg/
IGlar (95% CI)






























































CI conﬁdence interval, IDeg insulin degludec, IGlar insulin glargine, n number of patients, T1DMB/B basal–bolus-treated
type 1 diabetes mellitus, T2DMB/B basal–bolus-treated type 2 diabetes mellitus, T2DMinsulin-naı¨ve insulin-naı¨ve type 2
diabetes mellitus
* Signiﬁcant based on 95% CI
a ‘Nocturnal’ in the previously published analysis included all nocturnal events, severe and non-severe. In the current meta-
analysis, three mutually exclusive groups were deﬁned: non-severe nocturnal, non-severe daytime and severe hypoglycemia.
The deﬁnition of, and results for, severe episodes were similar in both analyses; therefore, severe episodes are not included in
the current meta-analysis
b Same assumptions as above. The maintenance period is from week 16 and onwards
Table 4 Observed daytime and nocturnal non-severe hypoglycemic events in the current meta-analysis [9–12, 14, 15]
Category Trials Daytime non-severe Nocturnal non-severe
n (total) Events/PYE n (total) Events/PYE
























IDeg insulin degludec, IGlar insulin glargine, n number of patients, PYE patient-year of exposure, T1DMB/B basal–bolus-
treated type 1 diabetes mellitus, T2DMB/B basal–bolus-treated type 2 diabetes mellitus, T2DMinsulin-naı¨ve insulin-naı¨ve type 2
diabetes mellitus
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(P\0.05) (T2DMinsulin-naı¨ve); and not analyzed
(T2DMB/B) due to too few events. Rate ratios for
daytime and nocturnal non-severe events in the
full trial and maintenance (week 16 onwards)
periods are shown in Table 5.
DISCUSSION
This meta-analysis showed that across
subgroups of patients with diabetes, those
treated with degludec achieve similar or
significantly better results than those treated
with glargine in terms of FPG and rates of
hypoglycemia, with similar reductions in
HbA1c. These results are achieved with lower
mean total insulin doses.
Non-inferiority of degludec with respect to
HbA1c lowering was confirmed (Table 2). Non-
inferiority is expected for treat-to-target trials
and was indeed seen in each trial. Nevertheless,
it is useful to confirm that, across different
subgroups, based on patient-level data, the
lower rates of hypoglycemia seen with
degludec are not obtained at a cost of inferior
glycemic control.
The individual trials had shown numerically
[9, 11, 14] or significantly greater reductions in
FPG [12, 15] with degludec. The current meta-
analysis showed significantly greater reductions
in FPG at trial end with degludec in both
T1DMB/B and T2DMinsulin-naı¨ve (0.61 and
0.34 mmol/L, respectively) (Table 2).
In the current meta-analysis of hypoglycemia
analyzed in mutually exclusive groups (Table 4),
rates of confirmed hypoglycemia in T2DM were
low and were generally in line with rates
observed in other trials. For example, among
insulin-naı¨ve patients, the non-severe confirmed
hypoglycemia rates with glargine were 2.05 and
3.0 events per patient-year, respectively, in the
current meta-analysis (Table 4) and in the treat-
to-target trial (which used a similar definition,
with confirmed events of B3.1 mmol/L) [21].
Corresponding nocturnal events were 0.51 and
1.3 per patient-year, respectively.
It is striking that despite the low
hypoglycemic event rates observed in trials, in
the current meta-analysis, rates of nocturnal
non-severe hypoglycemia were significantly
lower with degludec than with glargine in all
subgroups (Table 5). Rates of daytime non-
severe hypoglycemia were numerically lower
in T2DMinsulin-naı¨ve and significantly lower in
T2DMB/B with degludec (Table 5). Thus, the
lower rates of nocturnal non-severe events
observed with degludec do not occur at a cost
of higher daytime rates in T2DM. In T1DMB/B,
daytime non-severe rates were numerically but
not statistically higher with degludec (Table 5).
These results may have been confounded by the
unequal dose adjustment in the T1DMB/B trials
for patients randomized from twice-daily (BID)
insulin. For patients previously on BID insulin
who were randomized to glargine, a 20–30%
reduction in starting dose was recommended,
whereas patients randomized to degludec
maintained the same dose. This possibility is
further supported by the fact that during the
predefined maintenance phase ([16 weeks),
there was no increase in the risk of daytime
non-severe hypoglycemia with degludec.
Furthermore, these lower rates of nocturnal
non-severe hypoglycemia with degludec were
observed together with significantly or
numerically greater reductions in FPG values.
Lower FPG values would normally be expected
to be accompanied by higher rates of nocturnal
hypoglycemia, but with degludec, the reverse
was observed. This can most likely be attributed
to the stable and consistent profile of degludec,
with its long duration of action and lower day-
to-day pharmacodynamic variability compared
with glargine [5, 6].
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Hypoglycemia and fear of hypoglycemia
remain barriers to achieving target levels of
control [3]. In addition, hypoglycemia has
negative health-economic consequences such
as additional contacts with healthcare
professionals and absence from work following
an event, and these are particularly marked for
nocturnal hypoglycemia [22]. The possibility of
achieving lower FPG together with lower risk of
nocturnal hypoglycemia with degludec is,
therefore, valuable both to patients and in
terms of overall costs.
The value to patients of the lower risk of
hypoglycemia can be expressed in terms of
numbers needed to treat, as reported previously
[17]. In T2DMinsulin-naı¨ve, for every 100 people
treated with degludec instead of glargine for
1 year, 50 confirmed hypoglycemic episodes (of
which 20 are nocturnal) and two severe
episodes will be avoided. In T2DMB/B, for every
100 people treated with degludec instead of
glargine for 1 year, 326 confirmed
hypoglycemic episodes (of which 71 are
nocturnal) will be avoided. In T1DMB/B, for
every 100 subjects treated with degludec instead
of glargine for 1 year, 130 nocturnal confirmed
episodes will be avoided once the initial
titration phase has been completed.
These results are unlikely to have arisen
through bias. The trials in the BEGIN program
were open-label because blinding of treatment
would have been extremely difficult, given the
different insulin-delivery devices used. This
open-label design could have given rise to a
reporting bias in the patient-reported outcomes
of hypoglycemia, which would constitute a
limitation of the current study. There is no
reason to believe that such a bias was present,
and the requirement for patients to report only
confirmed episodes of hypoglycemia should
have limited any subjective influences.
Furthermore, the same titration algorithm was
used consistently across all trials for both basal
insulins to ensure that differences in titration
would not confound results.
Glargine was given according to its product
labeling (i.e., administered at any time of day as
advised by the investigator, at the same time
each day), whereas degludec was administered
once daily with the main evening meal, except
in BEGIN Once Asia, where it could be given
from the start of the evening meal to bedtime.
However, any effect of possible different timing
of administration of the two insulins is unlikely
to change the conclusions of the meta-analysis.
If glargine had systematically been given earlier
in the day than degludec, nocturnal
hypoglycemia would have been expected to be
lower with glargine. If, on the other hand, it
had been given later than degludec, any
increase in nocturnal hypoglycemia should
have been accompanied by greater decreases in
FPG with glargine.
End-of-trial total daily insulin doses were
significantly lower with degludec versus
glargine in T1DMB/B and T2DMinsulin-naı¨ve
(Table 3). This observation of lower doses with
degludec confirms the findings from individual
trials, with significantly lower end-of-trial mean
total insulin doses as follows: in T1DMB/B, 11%
lower in both the BEGIN BB T1 Long trial
(P\0.001) [9] and in the BEGIN Flex T1 trial
(statistical significance not reported) [10]; and
in T2DMinsulin-naı¨ve, 20% lower in BEGIN Once
Asia (P = 0.0004) [14] and 11% lower in BEGIN
Low Volume (P\0.05) [12]. In the third
T2DMinsulin-naı¨ve trial, BEGIN Once Long [15],
mean end-of-trial doses were not statistically
different for degludec and glargine.
With the exception of BEGIN Flex T1,
HRQoL was measured in all of the trials
included in this meta-analysis using the SF-36
questionnaire [23], which patients completed
themselves. As HRQoL results have already been
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published, HRQoL was not included in the
current meta-analysis. For T1DMB/B, there were
no significant between-treatment differences in
change from baseline in HRQoL in the BEGIN
BB T1 Long trial [9]. For T2DMinsulin-naı¨ve, a
meta-analysis examining HRQoL changes—
which included BEGIN Once Long, BEGIN
Once Asia and BEGIN Low Volume—reported
that, at endpoint, the overall physical health
component score was significantly better with
degludec versus glargine, due primarily to a
better score for degludec in the bodily pain
domain [19]. In the mental domains, the
vitality score was significantly better with
degludec. For T2DMB/B, HRQoL scores were
significantly better with degludec for the
domain of bodily pain [11]. A further meta-
analysis evaluated HRQoL expressed in terms of
health utility score (a value for estimating
quality of life) across all six BEGIN trials in
which HRQoL was measured [18]. Degludec was
associated with a modest but statistically
significant improvement in health utility
compared with glargine.
CONCLUSIONS
Compared with glargine, degludec is associated
with equivalent HbA1c control and significantly
lower nocturnal hypoglycemia rates. In patients
with T1DM and insulin-naı¨ve patients with
T2DM, degludec is also associated with
significantly greater reductions in FPG versus
glargine. Patients with T1DM and insulin-naı¨ve
patients with T2DM also required lower total
doses of insulin and all groups reported
improvements in HRQoL. It is possible that
these advantages—in particular, efficacious
lowering of FPG values together with lower
rates of nocturnal hypoglycemia—could
encourage physicians and patients to titrate
insulin regimens more rigorously to reach
glycemic target values.
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